Systemic Lupus Erythematosus-An Opinion Article

Maria Jose Moreno-Martinez1* and Manuel José Moreno Ramos2

1Rheumatology, Hospital Rafael Mendez, Lorca, Murcia, Spain
2Rheumatologist, Hospital Virgen de la, Arrixaca, Murcia Ctra. Madrid-Cartagena, Spain

*Corresponding author: Moreno-Martinez MJ, et al. Rheumatology, Hospital Rafael Mendez, Lorca, Murcia, Spain; Phone +0034647810640; Email: mjmorenomartinez@gmail.com

Received date: Oct 27, 2015; Accepted date: Nov 08, 2015; Published date: Nov 09, 2015

Copyright: © 2015 Moreno-Martinez MJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Opinion Article

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that causes frequent hematological disorders. Thrombocytopenia can occur in 30% of patients with SLE according to some series [1]. Typically, such alterations are controlled with classical immunosuppressants such as oral steroids, hydroxychloroquine, azathioprine and others. In some cases requires the use of more aggressive intravenous immunosuppression as cyclophosphamide, steroids and intravenous immunoglobulins, biological drugs or splenectomy [2].

We recently published the case of a 39 year old woman with SLE, severe thrombocytopenia (5000 platelets/microl) and day bleeding, refractory to different treatments (prednisone 0.5 mg/kg, mycophenolate 2 mg/kg/day, azathioprine 100 mg/day and rituximab). After discussing the case with hematology we decided to start therapy with eltrombopag (thrombopoietin-receptor agonist) [3].

Thrombopoietin induce megakaryocyte maturation [1]. In immune thrombocytopenia, autoantibodies produced by autoreactive B cells binding to megakaryocyte membranes could interfere with megakaryocyte maturation, thus resulting in decreased platelet production [2]. It has been shown anti-thrombopoietin antibodies in patients with SLE [4].

Thrombopoietin-receptor agonist is available in many countries for the treatment of chronic immune thrombocytopenia with an insufficient response to others immunosuppressants [5]. There have been reports of thrombocytopenia in patients with SLE who have been treated with these drugs with good results [3,4].

Thrombopoietin-receptor agonists also have side effects such as headache, nasopharyngitis, upper respiratory tract infection, fatigue and thrombosis [6]. In the case of SLE with secondary antiphospholipid syndrome, they have already been reported some cases in which there have been an increase of thrombosis in patients taking eltrombopag [7].

In patients with SLE and thrombocytopenia refractory to other treatments, thrombopoietin-receptor agonists can be a therapeutic alternative, but we must be cautious in patients at high risk of thrombotic events.

References